Influence of the gut microbiota on the response to immunotherapy in hepatocellular carcinoma DOI
Xiaomeng Wu, Terence K. Lee

Hepatoma Research, Journal Year: 2025, Volume and Issue: unknown

Published: May 29, 2025

For hepatocellular carcinoma (HCC) patients, the clinical efficacy of immune checkpoint inhibitors (ICIs) remains limited by low response rates. The gut microbiome as a critical modulator ICI responsiveness in HCC. We systematically analyze relevant microbial signatures distinguishing programmed death 1 therapy responders and non-responders, with particular emphasis on prognostic taxa. Microbiome-targeted interventions, encompassing antibiotic modulation, probiotic supplementation, prebiotic administration, fecal microbiota transplantation, may synergistically enhance ICIs leveraging immunomodulatory potential gut-derived metabolites. mechanisms governing microbiome-mediated immunotherapeutic regulation involve multifaceted interactions, particularly through microbiota-driven immunomodulation within tumor microenvironment. identify key translational challenges heterogeneity microbiomes. Future research directions emphasize need for standardized protocols, longitudinal cohort studies, innovative preclinical models to bridge existing knowledge gaps.

Language: Английский

Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies DOI Open Access

Valencia Mc Neil,

Seung Won Lee

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1408 - 1408

Published: April 23, 2025

A groundbreaking milestone in oncology has been the recognition and targeted elimination of malignant cells through cancer immunotherapy, which harnesses body’s immune system to attack [...]

Language: Английский

Citations

0
Duodenal mucosal ablation with irreversible electroporation reduces liver lipids in rats with non-alcoholic fatty liver disease DOI

Jiawei Yu,

Qi Zhao,

Peixi Li

et al.

World Journal of Gastroenterology, Journal Year: 2025, Volume and Issue: 31(16)

Published: April 25, 2025

Duodenal mucosal ablation (DMA) using irreversible electroporation (IRE) with a glucagon-like peptide-1 receptor agonist has been clinically shown to reduce liver lipid deposition in non-alcoholic fatty disease (NAFLD). However, the specific metabolic contributions of DMA IRE NAFLD remain unclear. To assess feasibility and effectiveness rat models. Seven-week-old male Sprague-Dawley rats underwent after 8 weeks on high-fat diet. Two post-treatment, duodenal tissues blood samples were collected. We evaluated differences wall structure, deposition, enteroendocrine, claudin, zonula ocludens-1 mucosa. could be safely performed without bleeding, perforation, or stenosis. The duodenum healed well 2 was characterized by slimmer villi, narrower shallower crypts, thicker myenterons compared sham-control setting. Liver reduced serum index parameters considerably improved these improvements independent food intake weight loss. In addition, enteroendocrine parameters, such as levels mucosa, differed between different settings group. By altering permeability, simple ameliorated rats.

Language: Английский

Citations

0
Influence of the gut microbiota on the response to immunotherapy in hepatocellular carcinoma DOI
Xiaomeng Wu, Terence K. Lee

Hepatoma Research, Journal Year: 2025, Volume and Issue: unknown

Published: May 29, 2025

For hepatocellular carcinoma (HCC) patients, the clinical efficacy of immune checkpoint inhibitors (ICIs) remains limited by low response rates. The gut microbiome as a critical modulator ICI responsiveness in HCC. We systematically analyze relevant microbial signatures distinguishing programmed death 1 therapy responders and non-responders, with particular emphasis on prognostic taxa. Microbiome-targeted interventions, encompassing antibiotic modulation, probiotic supplementation, prebiotic administration, fecal microbiota transplantation, may synergistically enhance ICIs leveraging immunomodulatory potential gut-derived metabolites. mechanisms governing microbiome-mediated immunotherapeutic regulation involve multifaceted interactions, particularly through microbiota-driven immunomodulation within tumor microenvironment. identify key translational challenges heterogeneity microbiomes. Future research directions emphasize need for standardized protocols, longitudinal cohort studies, innovative preclinical models to bridge existing knowledge gaps.

Language: Английский

Citations

0